NCT02411656 2026-01-23
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting